Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Recruiting
Eli Lilly and Company
Phase 1
This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and
preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1)
arginine 130 (R132)-mutant advanced solid tumors, including but not limited to
cholangiocarcinoma, chondrosarcoma, and glioma or isocitrate dehydrogenase 2 (IDH2) arginine
140 (R140) or arginine 172 (R172) mutant cholangiocarcinoma.
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Recruiting
Loxo Oncology, Inc.
Phase 1
This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and
preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1)
arginine 130 (R132)-mutant advanced solid tumors, including but not limited to
cholangiocarcinoma, chondrosarcoma, and glioma or isocitrate dehydrogenase 2 (IDH2) arginine
140 (R140) or arginine 172 (R172) mutant cholangiocarcinoma.
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
Recruiting
Eli Lilly and Company
Phase 1
This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent IDH
inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who
have received standard therapy
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
Recruiting
Loxo Oncology, Inc.
Phase 1
This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent IDH
inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who
have received standard therapy
Study of the Effects of Itraconazole and Carbamazepine on LY3410738 in Healthy Participants
Recruiting
Loxo Oncology, Inc.
Phase 1
The main purpose of this study is to learn about how itraconazole and carbamazepine affect
the levels of LY3410738 in the blood stream of healthy participants. Participation could last
up to 75 days.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
